On September 10, 2025, Travere Therapeutics announced that the FDA no longer requires an advisory committee for the review of their drug FILSPARI (sparsentan) for FSGS, with a decision expected by January 13, 2026; if approved, it would be the first treatment for this rare kidney disorder.